Get started
Author

Rafael Lluch

Observed names: R. Lluch, Rafael Lluch-García
Institution: Hospital de Manises
ORCID: 0000-0003-1358-5186
Observed ORCID: 0000-0003-1358-5186
OpenAlex ID: A5080067623
Management of acquired hemophilia A: results from the Spanish registry
2021 · María-Eva Mingot-Castellano, Josep Pardos-Gea, et al. · Blood Advances · 48
PDF
FatalStrongyloidesHyperinfection Complicating a Gram-Negative Sepsis after Allogeneic Stem Cell Transplantation: A Case Report and Review of the Literature
2013 · Isabel Izquierdo, Javier Briones, et al. · Case Reports in Hematology · 29
PDF
Geriatric assessment in hematology scale predicts treatment tolerability in older patients diagnosed with hematological malignancies: The RETROGAH study
2022 · Javier de la Rubia, Bernardo González, et al. · Journal of Geriatric Oncology · 21
PDF
WHO/ICC Classification for Myelodysplastic Neoplasms/Syndromes Performs Better for Subtype Cytomorphological Diagnosis?
2024 · Ana Isabel Vicente, Irene Luna, et al. · Diagnostics · 3
Data-driven flow cytometry classification of blast differentiation in older patients with acute myeloid leukemia
2024 · Catia Simoes, Carmen Gonzalez, et al. · Blood Neoplasia · 3
First worldwide real-life data on fixed-duration ibrutinib+venetoclax treatment for previously untreated CLL/SLL patients: Updated interim analysis of Spain´s LI+VE observational study
2025 · José Ángel Hernández-Rivas, Ana Muntanola Prat, et al. · Blood · 2
PDF
Real-world effectiveness and safety of zanubrutinib in Spanish patients with relapsed/refractory marginal zone lymphoma
2026 · Fernando Martin-Moro, Ana Muntañola, et al. · Blood Advances
Spanish real-life practice confirms zanubrutinib as a safe and effective option in relapsed or refractory marginal zone lymphoma: Results of a cohort of 118 patients on behalf of GELTAMO.
2025 · Ana Muntanola Prat, Fernando Martin-Moro, et al. · Blood
257 | Zanubrutinib in Relapsed/refractory Marginal Zone Lymphoma (r/r Mzl): Efficacy and Safety of 101 Spanish Patients Treated in the Real‐world on Behalf of Geltamo
2025 · F. Martin‐Moro, A. Muntañola, et al. · Hematological Oncology
PDF
Economic impact of sequencing treatments with oral therapies for chronic lymphocytic leukemia in Spain
2024 · Carlos Ulibarrena, Carmen Barrull, et al. · Revista Sangre (ENG)
PDF
Impacto económico de la secuenciación de tratamientos con terapias orales para la leucemia linfocítica crónica en España
2024 · Carlos Ulibarrena, Carmen Barrull, et al. · Revista Sangre
Percentage of Erythroid Cells in Bone Marrow at Diagnosis As a New Prognostic Factor in Patients with Myelodysplastic Syndrome
2018 · Ana Villalba, Leonor Senent, et al. · Blood
Prognostic Implication of the Percentage of Erythroid Cells in Bone Marrow at Diagnosis in Patients with Myelodysplastic Syndrome
2017 · L. Senent, I. Lorenzo, et al. · Leukemia Research
Renal Response in Patients with Relapsed Refractory Multiple Myeloma: Interim Data of a Large, Observational, Prospective Study
2016 · Javier De La Rubia, Queralt Salas, et al. · Blood
Works count: 14
Citation count: 106
H-index: 3
I10-index: 3
Year
Topic
Type